News for TXMD Stock

TherapeuticsMD Announces First Quarter 2025 Financial Results TherapeuticsMD Announces Full Year 2024 Financial Results TherapeuticsMD Announces Third Quarter 2024 Financial Results TherapeuticsMD Announces Second Quarter 2024 Financial Results TherapeuticsMD Announces First Quarter 2024 Financial Results TherapeuticsMD Announces Full Year 2023 Financial Results TherapeuticsMD Announces Third Quarter 2023 Financial Results TherapeuticsMD Announces Second Quarter 2023 Financial Results TherapeuticsMD Announces First Quarter 2023 Financial Results TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma TherapeuticsMD Announces Third Quarter 2022 Financial Results TherapeuticsMD Announces Additional $7 Million Private Placement TherapeuticsMD Announces $7 Million Private Placement TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers TherapeuticsMD Announces Second Quarter 2022 Financial Results TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022 TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital TherapeuticsMD Announces Expiration of Tender Offer EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA® TherapeuticsMD Announces First Quarter 2022 Financial Results TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022 TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million TherapeuticsMD Announces Fourth Quarter 2021 Financial Results TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022 Karen L. Ling joins Galderma’s Advisory Committee U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA® TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date TherapeuticsMD Announces Third Quarter 2021 Financial Results TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021 TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women* Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector TherapeuticsMD Announces Appointment of Hugh O’Dowd as President TherapeuticsMD Announces Second Quarter 2021 Financial Results TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021 TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award TherapeuticsMD Announces First Quarter 2021 Financial Results TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021 TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results TherapeuticsMD Announces Participation in Upcoming Investor Conferences TherapeuticsMD to Report Fourth Quarter 2020 Results on March 2, 2021 TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock TherapeuticsMD Announces Underwritten Public Offering of its Common Stock TherapeuticsMD Announces Participation in Upcoming Investor Conferences Comedian Whitney Cummings Partners with TherapeuticsMD to Launch “Just Say Vagina” TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock TherapeuticsMD Announces Participation in the Stifel 2020 Virtual Healthcare Conference TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock TherapeuticsMD Announces Underwritten Public Offering of its Common Stock TherapeuticsMD® Announces Third Quarter 2020 Financial Results POPSUGAR Launches New Women’s Health Destination, “Full Disclosure,” in Collaboration With TherapeuticsMD TherapeuticsMD Supports the Importance of Empowering Women to Make Informed Choices about their Sexual and Reproductive Health